The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI

Beijing Anzhen Hospital300 enrolled

Overview

The purpose of this study is to determine ticagrelor combining with low molecular weight heparin is effective and safe during PCI or not.

Ticagrelor is a new drug compared with clopidogrel. It has a stronger antiplatelet capacity. After PCI，whether using low molecular weight heparin can make patients better prognosis or not, What's more，full amount or half amount low molecular weight heparin?, also investigators want to explore that whether it may lead to more bleeding events.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

300

Conditions

LOVASTATIN/TICAGRELOR [VA Drug Interaction]

Interventions

TicagrelorDRUG

Patients were treated with full amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.

full amount low molecular weight heparinDRUG

Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.

half amount low molecular weight heparinDRUG

Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age ≥18 years old and ≤75 years ; 2. unstable angina, non-ST segment elevation acute myocardial infarction, old myocardial infarction, or confirm the presence of myocardial ischemia; 3. voluntary participation in clinical trials, and informed consent; Exclusion Criteria: 1. acute ST segment elevation myocardial infarction, stable angina pectoris; 2. aspirin allergy or resistance; 3. consolidated stroke, chronic obstructive pulmonary disease and other ticagrelor contraindications; 4. patients have coagulopathy; 5. can not be continued for one year with aspirin and treatment of dual antiplatelet ticagrelor; 6. can not complete revascularization; 7. NYHA ≥Ⅲ level or left ventricular ejection fraction \<40%; 8. severe liver and kidney dysfunction (ALT and AST were more than three times the upper limit of normal, creatinine clearance less than 30ml / min-1.1.72m-2);

Locations (1)

Beijing Anzhen Hosipital

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

all cause mortality

Time frame: one year

Secondary Outcomes

Nonfatal myocardial infarction

Patients occur acute myocardial infarction in a year，but it could not lead to die.

Time frame: one year

Non-fatal stroke

Patients occur stroke in a year，but it could not lead to die.

Time frame: one year

Revascularization again

Coronary arteries occur stenosis again in a year，the patients are treated with revascularization，including PCI and CABG.

Time frame: one year

Rehospitalization for ACS or heart failure

Patients are hospitalized again because of ACS or heart failure in a year.

Time frame: one year

Bleeding events

assessing the bleeding events according the TIMI grade.

Time frame: one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.